The Annual General Meeting of China Biopharmaceuticals will be held on 5 June 2024 at the Grand Hyatt Hong Kong Hotel and online via electronic conferencing system. The general meeting will discuss resolutions including the approval of the 2023 audited financial statements, the Board's report and the independent auditor's report, as well as the distribution of the final dividend for 2023. IN ADDITION, THE MEETING WILL RE-ELECT DIRECTORS, INCLUDING MR. XIE PING, MR. LU ZHENFEI AND MR. LI TAI KUI, AND AUTHORIZE THE BOARD TO DETERMINE THE DIRECTORS' REMUNERATION. Shareholders will also vote on the renewal of EY's accounting firm as auditor for the next financial year and authorise the Board to determine their remuneration. In addition, shareholders will vote...Show More

The Annual General Meeting of China Biopharmaceuticals will be held on 5 June 2024 at the Grand Hyatt Hong Kong Hotel and online via electronic conferencing system. The general meeting will discuss resolutions including the approval of the 2023 audited financial statements, the Board's report and the independent auditor's report, as well as the distribution of the final dividend for 2023. IN ADDITION, THE MEETING WILL RE-ELECT DIRECTORS, INCLUDING MR. XIE PING, MR. LU ZHENFEI AND MR. LI TAI KUI, AND AUTHORIZE THE BOARD TO DETERMINE THE DIRECTORS' REMUNERATION. Shareholders will also vote on the renewal of EY's accounting firm as auditor for the next financial year and authorise the Board to determine their remuneration. In addition, shareholders will vote on the Directors' general authorization to issue and repurchase shares, including the issuance of additional shares not exceeding 20% of the issued share capital and the repurchase of shares not exceeding 10% of the issued share capital. Shareholders may appoint representatives to attend and vote at the General Meeting by completing the Proxy Form, or elect to attend the meeting in person.